Company Overview - Tsinghua Tongfang Co., Ltd. is located in Beijing and was established on January 11, 1999, with its listing date on October 30, 2009. The company operates in two main business segments: outdoor products and semiconductor chips, which belong to the outdoor goods industry and semiconductor industry respectively [1] - The revenue composition of Tsinghua Tongfang includes outdoor clothing (63.31%), chip business (17.13%), outdoor footwear (13.29%), outdoor equipment (3.71%), and other service businesses (2.56%) [1] Financial Performance - For the first half of 2025, Tsinghua Tongfang reported a revenue of 653 million yuan, a year-on-year decrease of 7.82%. The net profit attributable to shareholders was 20.09 million yuan, down 76.50% year-on-year [2] - Since its A-share listing, Tsinghua Tongfang has distributed a total of 509 million yuan in dividends, with 30.42 million yuan distributed over the past three years [3] Stock Market Activity - On September 12, Tsinghua Tongfang's stock price decreased by 2.01%, trading at 9.28 yuan per share with a total market capitalization of 8.201 billion yuan. The trading volume was 114 million yuan, with a turnover rate of 1.38% [1] - Year-to-date, Tsinghua Tongfang's stock price has increased by 32.59%, but it has seen a decline of 3.33% over the last five trading days and a slight decrease of 1.17% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on April 30, where it recorded a net purchase of 115 million yuan [1] Shareholder Information - As of June 30, Tsinghua Tongfang had 58,000 shareholders, an increase of 31.04% from the previous period. The average number of tradable shares per shareholder was 15,220, a decrease of 23.69% [2]

Core Viewpoint - The stock of Aide Biological experienced a decline of 2.03% on September 12, with a current price of 23.66 CNY per share and a total market capitalization of 9.264 billion CNY, indicating a mixed performance in recent trading sessions [1]. Financial Performance - For the first half of 2025, Aide Biological reported a revenue of 579 million CNY, representing a year-on-year growth of 6.69%, and a net profit attributable to shareholders of 189 million CNY, which is a 31.41% increase compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 421 million CNY, with 232 million CNY distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 5.41% to 25,300, while the average circulating shares per person decreased by 5.13% to 15,393 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 31.6706 million shares, a decrease of 3.5159 million shares from the previous period [3]. - New entrants among the top ten circulating shareholders include Hua Bao Zhong Zheng Medical ETF, holding 9.0366 million shares [3]. Stock Performance - Year-to-date, Aide Biological's stock price has increased by 5.16%, but it has seen a decline of 4.56% over the last five trading days and a slight decrease of 1.05% over the past 20 days [1]. - The stock has shown a more favorable performance over the last 60 days, with an increase of 13.15% [1]. Business Overview - Aide Biological, established on February 21, 2008, and listed on August 2, 2017, specializes in the research, production, and sales of molecular diagnostic products for precision oncology, along with related testing services [1]. - The company's revenue composition includes 83.43% from testing reagents, 9.84% from clinical research services, 5.61% from testing services, and 1.12% from other sources [1].

Company Overview - Runhe Materials Co., Ltd. is located in Ningbo, Zhejiang Province, established on December 6, 2000, and listed on November 27, 2017. The company specializes in the research, production, and sales of organic silicon deep processing products and textile printing and dyeing auxiliaries [1][2]. Financial Performance - For the first half of 2025, Runhe Materials achieved operating revenue of 679 million yuan, representing a year-on-year growth of 4.16%. The net profit attributable to the parent company was 57.75 million yuan, showing a significant year-on-year increase of 38.61% [2]. - Since its A-share listing, the company has distributed a total of 171 million yuan in dividends, with 87.45 million yuan distributed over the past three years [3]. Stock Performance - As of September 12, Runhe Materials' stock price increased by 2.17% to 42.30 yuan per share, with a total market capitalization of 7.608 billion yuan. The stock has risen 64.44% year-to-date, with a 0.76% increase over the last five trading days, 16.30% over the last 20 days, and 66.01% over the last 60 days [1]. - The company has a total of 12,400 shareholders as of June 30, which is an increase of 26.03% from the previous period, with an average of 13,012 circulating shares per shareholder, up by 6.03% [2]. Business Segmentation - The main business revenue composition of Runhe Materials includes organic silicon deep processing products at 64.53%, textile printing and dyeing auxiliaries at 35.32%, and other products at 0.15% [1]. - The company is categorized under the Shenwan industry classification as basic chemicals - chemical products - organic silicon, and is associated with concepts such as liquid cooling, medical devices, share buybacks, small-cap stocks, and semiconductors [1].

Core Viewpoint - Long Yong Co., Ltd. has shown a significant increase in stock price and trading activity, indicating positive market sentiment and potential growth opportunities in the printing and packaging equipment sector [1][2]. Group 1: Stock Performance - As of September 12, Long Yong's stock price increased by 2.10%, reaching 8.26 CNY per share, with a total market capitalization of 3.5 billion CNY [1]. - Year-to-date, Long Yong's stock price has risen by 46.71%, with a 3.64% increase over the last five trading days, 4.42% over the last twenty days, and 29.06% over the last sixty days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 15, where it recorded a net buy of -121 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Long Yong reported operating revenue of 726 million CNY, a year-on-year decrease of 3.80%, while net profit attributable to shareholders increased by 156.45% to 5.02 million CNY [2]. - Cumulatively, Long Yong has distributed 827 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Company Overview - Long Yong Co., Ltd. is located in the Beichen Economic Development Zone of Tianjin and was established on September 13, 1995, with its listing date on March 29, 2011 [1]. - The company's main business involves the research, development, manufacturing, and sales of printing and packaging equipment, with revenue composition as follows: 88.31% from equipment manufacturing and system solutions, 4.86% from financial leasing, 4.59% from operational leasing, and 1.28% from other sources [1].

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, with ongoing development of customized dental implants [2][3] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is located in Tongzhou District, Beijing, specializing in implantable orthopedic medical devices [7][8] - The company's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][3][8] Financial Performance - For the first half of 2025, Spring Medical achieved operating revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position, innovation capabilities, and high market share [3] - The company is actively involved in the smart medical field, having obtained registration certificates for hip and knee surgical robots and medical image processing software [2][3] Stock Performance - On September 11, Spring Medical's stock rose by 1.94%, with a trading volume of 48.86 million yuan and a market capitalization of 9.267 billion yuan [1] - The average trading cost of the stock is 20.64 yuan, with the current price fluctuating between resistance at 25.91 yuan and support at 22.65 yuan [6]

Company Overview - Opcon Vision, established on October 26, 2000, and listed on January 17, 2017, is located in Hefei, Anhui Province. The company specializes in the research, production, and sales of optical products and related services [1][2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2]. - The company has distributed a total of 897 million yuan in dividends since its A-share listing, with 526 million yuan distributed over the past three years [3]. Stock Performance - As of September 11, Opcon Vision's stock price increased by 2.03% to 18.11 yuan per share, with a trading volume of 128 million yuan and a turnover rate of 1.07%, resulting in a total market capitalization of 16.229 billion yuan [1]. - Year-to-date, the stock price has decreased by 3.29%, with a 3.72% increase over the last five trading days, a 2.42% decrease over the last 20 days, and a 23.37% increase over the last 60 days [1]. Shareholder Structure - As of August 29, the number of shareholders for Opcon Vision was 61,700, a decrease of 3.70% from the previous period, with an average of 10,832 circulating shares per shareholder, an increase of 3.84% [2]. - The top ten circulating shareholders include significant institutional investors, with notable increases in holdings from various ETFs [3].

Core Viewpoint - The stock of Haishike has shown significant performance with a year-to-date increase of 76.74%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 11, Haishike's stock price reached 58.29 CNY per share, with a market capitalization of 65.28 billion CNY [1]. - The stock has experienced a 1.78% increase over the last five trading days and a 37.93% increase over the last 60 days [1]. - The company has seen a net outflow of 4.30 million CNY in principal funds, with large orders showing a buy of 14.74 million CNY and a sell of 19.74 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.00 billion CNY, reflecting an 18.63% year-on-year growth, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. - Cumulatively, the company has distributed 3.67 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per person, down by 28.64% [2]. - The top ten circulating shareholders include several mutual funds, with notable increases in holdings from institutions such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3].

Core Viewpoint - The company Aidi Te (Qinhuangdao) Technology Co., Ltd. is experiencing growth in its dental medical and 3D printing sectors, benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][4]. Company Overview - Aidi Te specializes in the research, production, and sales of dental restoration materials and digital dental equipment, with main products including dental restoration materials, digital dental devices, orthodontic products, and preventive dental products [2][4]. - The company was established on March 15, 2007, and went public on June 26, 2024. Its revenue composition includes 73.74% from dental restoration materials, 19.80% from digital dental equipment, and 6.46% from other products and services [8]. Financial Performance - For the first half of 2025, Aidi Te achieved a revenue of 486 million yuan, representing a year-on-year growth of 17.22%, and a net profit attributable to shareholders of 92.04 million yuan, up 19.86% year-on-year [8]. - The company's overseas revenue accounted for 61.85% of total revenue, benefiting from the depreciation of the RMB [4]. Market Position - Aidi Te has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is categorized under small-cap stocks, medical devices, newly listed stocks, 3D printing, and specialized innovation concepts [8]. Stock Performance - On September 10, the stock price of Aidi Te increased by 0.15%, with a trading volume of 43.94 million yuan and a market capitalization of 4.925 billion yuan [1]. - The average trading cost of the stock is 48.70 yuan, with the current price approaching a resistance level of 46.78 yuan, indicating potential for upward movement if this level is surpassed [7].

Core Viewpoint - Tianyi Medical's stock price has shown a significant increase of 25.00% year-to-date, indicating strong market performance despite a recent decline over the past 20 days [1] Company Overview - Tianyi Medical, established on March 12, 1998, is located in Ningbo, Zhejiang Province, and was listed on April 7, 2022 [1] - The company specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1] - Revenue composition: Blood purification accounts for 59.05%, ward care for 34.08%, and other products for 6.87% [1] Financial Performance - For the first half of 2025, Tianyi Medical reported revenue of 227 million yuan, a year-on-year increase of 11.50%, while net profit attributable to shareholders was 9.48 million yuan, a decrease of 35.23% [1] - Cumulative cash distribution since the A-share listing amounts to 102 million yuan, with 87.5 million yuan distributed over the past three years [2] Shareholder Information - As of June 30, 2025, the number of shareholders is 4,196, a slight decrease of 0.31% from the previous period [1] - The average number of circulating shares per shareholder is 4,372, which has increased by 0.31% [1] - Major shareholders include Penghua Hongjia Mixed A and Yuanxin Yongfeng Ju You A, with some changes in holdings noted [2]

Core Viewpoint - The stock price of Opcon Vision has shown fluctuations, with a slight increase on September 8, 2023, but a decline in the year-to-date performance, indicating potential concerns regarding its market position and financial health [1][2]. Company Overview - Opcon Vision Technology Co., Ltd. was established on October 26, 2000, and listed on January 17, 2017. The company specializes in the research, production, and sales of optical products and related services [2]. - The company's revenue composition includes: hard contact lenses (40.86%), other optical products and technical services (21.52%), medical services (19.89%), nursing products (12.57%), non-optical products (4.60%), and other (0.55%) [2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 897 million yuan in dividends, with 526 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Opcon Vision was 61,700, a decrease of 3.70% from the previous period, with an average of 10,832 circulating shares per person, an increase of 3.84% [2]. - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, all of which have increased their holdings compared to the previous period [3].